Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 27,000 shares at $29.34 ($799K) on 2026-07-01, disclosed to the SEC on 2026-07-02.
Scheduled sale ($799k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.34 | 19,629 | $576K | 72.1% |
| 2 | $30.25 | 7,371 | $223K | 27.9% |
| Total | $29.59 avg | 27,000 | $799K | 100% |
| Filing → |
| TNGX | SELL | 2026-08-05 | $736K | — | Filing → |
| TNGX | SELL | 2026-06-03 | $618K | — | Filing → |
| TNGX | SELL | 2026-05-05 | $573K | — | Filing → |